With snowballing healthcare spending and the emergence of new modalities of treatments, discussions are heating up around revisiting the scope of health coverage on pharmaceuticals, with the Ministry of Finance (MOF) and payers advocating the mantra of “large risks with…
HOME > BUSINESS
BUSINESS
- Astellas to Make US$13 Million Investment in Boston Area to Support Startups
October 3, 2019
- Health Canada Accepts Mitsubishi Tanabe’s Plant-Derived Flu Vaccine for Review
October 3, 2019
- Nippon Shinyaku Seeks US Approval for DMD Therapy Viltolarsen
October 3, 2019
- Asahi Kasei Sues Endo over Xiaflex Supply Halt
October 2, 2019
- Axcelead Gets Its Hands on PassPort’s Transdermal Drug Delivery Technology
October 2, 2019
- Taisho Grabs Japan Rights to Moberg’s Topical Onychomycosis Drug
October 2, 2019
- Nippon Zoki to Develop Its 1st Biologic by Licensing Bone Forming Promoting Drug from South Korean Biotech
October 2, 2019
- Eisai, US Merck Present Final PII Results for Lenvima/Keytruda Combo for Endometrial Cancer
October 2, 2019
- Tsuyoshi Mitsuhashi Appointed as New President of Konica Minolta Precision Medicine
October 2, 2019
- Opdivo Significantly Extends OS against Chemo in Esophageal Cancer
October 2, 2019
- Takara Bio Drops Oncolytic Virus Filing for Melanoma in Japan
October 1, 2019
- ADC-Keytruda Combo Shows ORR of 71% in 1st Line Bladder Cancer: Astellas/Seattle Genetics
October 1, 2019
- Avanir’s AVP-786 Misses Goals in PIII for Moderate-to-Severe Agitation in AD Patients
October 1, 2019
- Eisai, Nichi-Iko Team Up for Generic Business in China
October 1, 2019
- AZ to Focus on Asthma-COPD Overlap in Marketing Triple-Combo Therapy Breztri, Will Help GPs Make Diagnosis
September 30, 2019
- GSK Recalls Zantac as Preventive Measure for NDMA Carcinogenic Risk
September 30, 2019
- Nippon Shinyaku Submits Sakigake DMD Drug Viltolarsen in Japan, Could Be Approved by March
September 27, 2019
- Meiji Seika’s Korean JV Passes GMP Inspection by PMDA, Preparing for Contract Production of Nesp Biosimilar
September 27, 2019
- Otsuka Files for Abilify Once-Monthly Injection for Bipolar Disorder in Japan
September 27, 2019
- Takeda’s Sakigake-Designated Narcolepsy Drug Prolongs Sleep Latency in PI
September 27, 2019
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…